Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Jonnyboy85on Apr 05, 2021 1:16am
94 Views
Post# 32935964

RE:Multiple tests, FDA path and I think you know which partner.

RE:Multiple tests, FDA path and I think you know which partner.How bout a recap for OlEurAnus:)
Jonnyboy85 wrote: https://daveasprey.com/dr-charles-meakin-801/


Excerpts from the transcription of the podcast with Dr. Charles Meakin,


Charles:


We believe the tentative name will be alert and avert. We want to use these four drugs for two weeks, strangely, you said that in a lighter dose, and then couple that with some metabolic with nutritional training, and couple that as well with after two weeks, take five supplements that they would do for another 10 weeks, and then repeat that 12 weeks cycle four times a year. We roll this out for the high risk individuals like the genetic risk bracket one, bracket two, and then pilots and firemen and people with higher levels of cancer in their family. Disclaimer: Bulletproof Radio transcripts are prepared by a transcription service. Refer to full audio for exact wording.


The beauty of this as well is our potential partner, we're working out in a sprint way the agreement now, has a blood test, a blood biopsy, more or less, that works on looking at mRNA pathways, and what the body's doing internally with eight markers. These eight markers predict four green light, very low risk, you're in balance and doing things well, versus an amber light, which might be some things are at risk versus red light, which means you need to repeat your basic screening because something is going on. Then we would do that at the beginning of the year and then at the end of the year, and verify which this combination of supplements and medications should self-correct these metabolic abnormalities, and get them back on track. We suspect this might be able to reduce cancer risk from 25% to 50%.


Charles: Yes. No, it'd be do the blood test, and then do the two weeks of the four drugs under a physician oversight, because we do want to test a few blood tests that we'd want to make sure are normal, and then do the five supplements, then total 12 weeks and then repeat that. We would do this for people. I mean, there's 14 million people walking around who've been treated for cancer or in limbo, not sure if it's going to come back or not, probably holding off on life decisions. This blood test will greatly help them, and then for those people we treat with the metabolic treatment, we usually do that intensely for 18 to 24 months.


Charles: Disclaimer: Bulletproof Radio transcripts are prepared by a transcription service. Refer to full audio for exact wording. Well, they say in 2021, there's going to be two or three blood biopsies, and they're based on different... Our partner is looking at mRNA, but there's also a group looking at methylation patterns and that prediction for cancer. There's also others looking at protein breakdown, products in the blood that may reflect cancer, and then there's other looking at nucleic acid or DNA breakdown products. They all have variable specificity and sensitivities. Right now, that work is not totally sound. When we roll all ours out, we're hoping that it's going to be in a... We're working with the FDA now with a clinical research group to have an FDA path so that when we generate data on this, we'll be able to publish results in a peer-reviewed journal.


<< Previous
Bullboard Posts
Next >>